IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

Cited by (1,000)

Items 101–200 of 1,000

1. Chondrosarcoma: biology, genetics, and epigenetics
   Warren Allen Chow · 2018 · F1000Research
2. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft
   Alexandra Borodovsky, Vafi Salmasi, Şevin Turcan, Armida W. M. Fabius, Gilson Soares Baía, Charles G. Eberhart, JON D. WEINGART, Gary L. Gallia, Stephen B. Baylin, Timothy An-thy Chan et al. · 2013 · Oncotarget
3. Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma
   Meng‐Ju Wu, Lei Shi, Juan Dubrot, Joshua Merritt, Vindhya Vijay, Ting-Yu Wei, Emily Kessler, Kira E. Olander, Ramzi Adil, Amaya Pankaj et al. · 2021 · Cancer Discovery
4. Isocitrate dehydrogenase‐mutant glioma: Evolving clinical and therapeutic implications
   Julie J. Miller, Helen Alice Shih, Ovidiu C. Andronesi, Daniel P. Cahill · 2017 · Cancer
5. Chondroblastoma: An Update
   Wenqian Chen, Lisa Difrancesco · 2017 · Archives of Pathology & Laboratory Medicine
6. Targeting cancer metabolism
   Teicher, Beverly A., Linehan, W. Marston, Helman, Lee J. · 2012 · Clinical Cancer Research
7. Refinements in Sarcoma Classification in the Current 2013 World Health Organization Classification of Tumours of Soft Tissue and Bone
   Vickie Y. Jo, Leona A. Doyle · 2016 · Surgical Oncology Clinics of North America
8. Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives
   Yongcheng Song, Fangrui Wu, Jingyu Wu · 2016 · Journal of Hematology & Oncology
9. Oncometabolites‐driven tumorigenesis: From genetics to targeted therapy
   Aurélie Morin, Éric Letouzé, Anne‐Paule Gimenez‐Roqueplo, Judith Favier · 2014 · International Journal of Cancer
10. Oncometabolites: tailoring our genes
    Stefan Nowicki, Eyal Gottlieb · 2015 · FEBS Journal
11. Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling
    Laurence M. Gagné, Karine Boulay, Ivan Topisirović, Marc‐Étienne Huot, Frédérick A. Mallette · 2017 · Trends in Cell Biology
12. Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism
    Di Yu, Yang Liu, Yiqiang Zhou, Victor Ruiz‐Rodado, Mioara Larion, Guowang Xu, Chunzhang Yang · 2020 · Proceedings of the National Academy of Sciences
13. The imaging of cartilaginous bone tumours. I. Benign lesions
    Hassan Douis, Asif Saifuddin · 2012 · Skeletal Radiology
14. Metabolomic Analysis of Bone Morphogenetic Protein Receptor Type 2 Mutations in Human Pulmonary Endothelium Reveals Widespread Metabolic Reprogramming
    Joshua P. Fessel, Rizwan Hamid, Bryan M. Wittmann, Linda J. Robinson, Tom Blackwell, Yuji Tada, Nobuhiro Tanabe, Koichiro Tatsumi, Anna Ryan Hemnes, James D. West · 2012 · Pulmonary Circulation
15. TP53 in bone and soft tissue sarcomas
    Elizabeth A. Thoenen, Amanda Curl, Tomoo Iwakuma · 2019 · Pharmacology & Therapeutics
16. Lower Grade Gliomas
    Gilbert Youssef, Julie J. Miller · 2020 · Current Neurology and Neuroscience Reports
17. IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity
    Sarah Chiang, Britta Weigelt, Huei‐Chi Wen, Fresia G. Pareja, Ashwini Raghavendra, Luciano Gastón Martelotto, Kathleen A. Burke, Thais Basili, Anqi Li, Felipe Correa Geyer et al. · 2016 · Cancer Research
18. 2-Hydroxyglutarate in Cancer Cells
    Ježek, Petr · 2020 · Antioxidants & Redox Signaling
19. DNA methylation-based classification of sinonasal undifferentiated carcinoma
    Snjezana Doğan, Varshini Vasudevaraja, Bin Xu, Jonathan Serrano, Ryan N. Ptashkin, Hun Jae Jung, Sarah Chiang, Achim A. Jungbluth, Marc A. Cohen, Ian Ganly et al. · 2019 · Modern Pathology
20. Role of DNMT3A, TET2, and IDH1/2 mutations in pre-leukemic stem cells in acute myeloid leukemia
    Steven M. Chan, Ravindra Majeti · 2013 · International Journal of Hematology
21. Molecular pathogenesis of IDH mutations in gliomas
    Koichi Ichimura · 2012 · Brain Tumor Pathology
22. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing
    Shipra Agarwal, Mehar Chand Sharma, Pankaj Jha, Pankaj Pathak, Vaishali S. Suri, Chitra Sarkar, Kunzang Chosdol, A. Suri, Shashank Sharad Kale, A. K. Mahapatra et al. · 2013 · Neuro-Oncology
23. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma
    Chunzhi Zhang, Lynette M. Moore, Xia Li, W. K. Alfred Yung, Wei Zhang · 2013 · Neuro-Oncology
24. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M
    Michael J. Karsy, Jian Guan, Adam Louis Cohen, Randy L. Jensen, Howard Colman · 2017 · Current Neurology and Neuroscience Reports
25. Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight
    Hamoud Al‐Khallaf · 2017 · Cell & Bioscience
26. Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo
    Anuhar Chaturvedi, Lena Herbst, Stefan Pusch, Lara C. Klett, Ramya Goparaju, Damian Stichel, Silke Kaulfuß, Olaf Panknin, Katja C. Zimmermann, Luisella Toschi et al. · 2017 · Leukemia
27. Chondrosarcoma: A Clinical Review
    Aaron Gazendam, Snežana Popović, Naveen Parasu, Michelle A. Ghert · 2023 · Journal of Clinical Medicine
28. Isocitrate Dehydrogenase (IDH) Mutations Promote a Reversible ZEB1/MicroRNA (miR)-200-dependent Epithelial-Mesenchymal Transition (EMT)
    Alexandra R. Grassian, Fallon Lin, Rosemary Barrett, Yue Liu, Wei Jiang, Manav Korpal, Holly M. Astley, Daniel P. Gitterman, Thomas Henley, Rob Howes et al. · 2012 · Journal of Biological Chemistry
29. Alterations of metabolic genes and metabolites in cancer
    Eric Karl Oermann, Jing Wu, Kun‐Liang Guan, Yue Xiong · 2012 · Seminars in Cell and Developmental Biology
30. Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype
    Marie Kostine, Arjen H.G. Cleven, Noel F.C.C. de Miranda, Antoîne Italiano, Anne‐Marie Cleton-Jansen, Judith V.M.G. Bovée · 2016 · Modern Pathology
31. Genetic alterations in Krebs cycle and its impact on cancer pathogenesis
    Karishma Sajnani, Farhadul Islam, Robert Anthony Smith, Vinod Gopalan, Alfred King-yin Lam · 2017 · Biochimie
32. Emerging Epigenetic Targets and Therapies in Cancer Medicine
    Relja Popovic, Jonathan D. Licht · 2012 · Cancer Discovery
33. Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma
    Vickie Y. Jo, Nicole Grace Chau, Jason L. Hornick, Jeffrey F. Krane, Lynette Marie Sholl · 2017 · Modern Pathology
34. Mutant <i>IDH</i> is sufficient to initiate enchondromatosis in mice
    Hirata, Makoto, Sasaki, Masato, Cairns, Rob A., Inoue, Satoshi, Puviindran, Vijitha, Li, Wanda Y., Snow, Bryan E., Jones, Lisa D., Wei, Qingxia, Sato, Shingo et al. · 2015 · Proceedings of the National Academy of Sciences
35. 5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy
    Aparna Vasanthakumar, Lucy A. Godley · 2015 · Cancer Genetics
36. Molecular mechanisms underpinning sarcomas and implications for current and future therapy
    Victoria Damerell, Michael Sean Pepper, Sharon Prince · 2021 · Signal Transduction and Targeted Therapy
37. Frequent IDH2 R172 mutations in undifferentiated and poorly‐differentiated sinonasal carcinomas
    Snjezana Doğan, Deborah J. Chute, Bin Xu, Ryan N. Ptashkin, Raghu Chandramohan, Jacklyn Casanova, Khédoudja Nafa, Justin A. Bishop, Simion I. Chiosea, Edward B. Stelow et al. · 2017 · The Journal of Pathology
38. Genetic and epigenetic determinants of AML pathogenesis
    Sheng F. Cai, Ross L. Levine · 2018 · Seminars in Hematology
39. Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma
    Daniëlle Meijer, Daniëlle de Jong, Twinkal C. Pansuriya, Brendy E. van den Akker, Piero Picci, Károly Szuhai, Judith V.M.G. Bovée · 2012 · Genes Chromosomes and Cancer
40. Chordoma
    Veronica Ulici, Jesse L. Hart · 2021 · Archives of Pathology & Laboratory Medicine
41. Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas
    Yuxiang Wang, Aaron Tyler Wild, Şevin Turcan, Wei Wu, Carlie Sigel, David S. Klimstra, Xiaoxiao Ma, Yongxing Gong, Eric C. Holland, Jason T. Huse et al. · 2020 · Science Advances
42. Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
    Xiaoyan Liu, Yuping Gong · 2019 · Biomarker Research
43. Biomarkers of Osteosarcoma, Chondrosarcoma, and Ewing Sarcoma
    Giuseppe Evola, Luciano Costarella, Vito Pavone, Giuseppe Caff, Luca Cannavò, Andrea Sessa, Sergio Avondo, Giuseppe Sessa · 2017 · Frontiers in Pharmacology
44. The Metabolic Alterations of Cancer Cells
    Marco Sciacovelli, Edoardo Gaude, Mika Hilvo, Christian Frezza · 2014 · Methods in enzymology on CD-ROM/Methods in enzymology
45. The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells
    Katarína Smolková, Petr Ježek · 2012 · International Journal of Cell Biology
46. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells
    Luyuan Li, Ana Cristina Paz, Breelyn Ann Wilky, Britt A. Johnson, Karina A. Galoian, Andrew Eric Rosenberg, Guozhi Hu, Gabriel Tinoco, Olaf A. Bodamer, Jonathan C. Trent · 2015 · PLoS ONE
47. Synovial chondromatosis and soft tissue chondroma: extraosseous cartilaginous tumor defined by FN1 gene rearrangement
    Fernanda M Amary, Luis Pérez-Casanova, Hongtao Ye, Lucia Cottone, Anna‐Christina Strobl, Paul Cool, Elena Miranda, Fitim Berisha, William J.S. Aston, Ana Maia Rocha et al. · 2019 · Modern Pathology
48. Molecular Distinction of Chondrosarcoma From Chondroblastic Osteosarcoma Through IDH1/2 Mutations
    Darcy A. Kerr, Hector U. Lopez, Vikram Deshpande, Francis John Hornicek, Zhenfeng Duan, Yaxia Zhang, Andrew Eric Rosenberg, Darrel R. Borger, G. Petur Nielsen · 2013 · The American Journal of Surgical Pathology
49. New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma
    Lilia Dimitrov, Christopher S. Hong, Chunzhang Yang, Zhengping Zhuang, John D. Heiss · 2015 · International Journal of Medical Sciences
50. Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression
    Rémy Nicolle, Mira Ayadi, Anne Gomez‐Brouchet, Lucile Armenoult, Guillaume Banneau, Nabila Elarouci, Matthias Tallegas, Anne‐Valérie Decouvelaere, Sébastien Aubert, Françoise Rédiní et al. · 2019 · Nature Communications
51. Mesenchymal stem cell transformation and sarcoma genesis
    Wei Xiao, Alexander B. Mohseny, Pancras C.W. Hogendoorn, Anne‐Marie Cleton-Jansen · 2013 · Clinical Sarcoma Research
52. Chondrosarcoma
    Robert Carl Weinschenk, Wei‐Lien Wang, Valerae Olive Lewis · 2021 · Journal of the American Academy of Orthopaedic Surgeons
53. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines
    Johnny Suijker, Jan Oosting, Annemarie Koornneef, Eduard A. Struys, Gajja Sophi Salomons, Frank G. Schaap, Cathelijn J. F. Waaijer, Pauline M. Wijers‐Koster, Inge H. Briaire‐de Bruijn, Lizette C. J. M. Haazen et al. · 2015 · Oncotarget
54. Blockade of Glutathione Metabolism in IDH1 -Mutated Glioma
    Xiaoying Tang, Xiao Fu, Yang Liu, Di Yu, Sabrina J. Cai, Chunzhang Yang · 2019 · Molecular Cancer Therapeutics
55. The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis
    Tianxiang Wang, Jun-Yun Liang, Cheng Zhang, Yue Xiong, Kun‐Liang Guan, Hai‐Xin Yuan · 2019 · Cell Death and Disease
56. Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation
    Aizhen Liu, Chunfeng Hou, Hongfang Chen, Xuan Zong, Peijun Zong · 2016 · Frontiers in Oncology
57. The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma
    Charlotte Pawlyn, Martin Kaiser, Christoph Johann Heuck, Lorenzo Melchor, Christopher P. Wardell, Alex Murison, Shweta S. Chavan, David C. Johnson, Dil B Begum, Nasrin M. Dahir et al. · 2016 · Clinical Cancer Research
58. Insights into Enchondroma, Enchondromatosis and the risk of secondary Chondrosarcoma. Review of the literature with an emphasis on the clinical behaviour, radiology, malignant transformation and the follow up
    Georg Werner Herget, P Strohm, Christof Rottenburger, Udo Kontny, Tobias Krauß, Jens Böhm, Norbert Paul Südkamp, Markus Uhl · 2014 · Neoplasma
59. Unique mutation portraits and frequent COL2A1 gene alteration in chondrosarcoma
    Yasushi Totoki, Akihiko Yoshida, Fumie Hosoda, Hiromi K. Nakamura, Natsuko Hama, Koichi Ogura, Aki Yoshida, Tomohiro Fujiwara, Yasuhito Arai, Junya Toguchida et al. · 2014 · Genome Research
60. 5-Hydroxymethylcytosine: An epigenetic mark frequently deregulated in cancer
    Leonie I. Kroeze, Bert A. van der Reijden, Joop H. Jansen · 2015 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
61. Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets
    Elahe Nazeri, Mohammad Gouran‐Savadkoohi, Keivan Majidzadeh‐A, Rezvan Esmaeili · 2018 · Critical Reviews in Oncology/Hematology
62. An update of molecular pathology of bone tumors. Lessons learned from investigating samples by next generation sequencing
    Daniel Baumhoer, Fernanda M Amary, Adrienne Margaret Flanagan · 2018 · Genes Chromosomes and Cancer
63. Natural history of Ollier disease and Maffucci syndrome: Patient survey and review of clinical literature
    Jad M. El Abiad, Sarah M. Robbins, BERNARD ALLAN COHEN, Adam Scott Levin, David L. Valle, Carol D. Morris, Nara Lygia de Macena Sobreira · 2020 · American Journal of Medical Genetics Part A
64. Emerging Targeted and Immune-Based Therapies in Sarcoma
    Seth M. Pollack, Matthew A. Ingham, Matthew B. Spraker, Gary K. Schwartz · 2017 · Journal of Clinical Oncology
65. Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma
    Guo Gord Zhu, Khédoudja Nafa, Narasimhan P. Agaram, Ahmet Zehir, Ryma Benayed, Justyna Sadowska, Laetitia A Borsu, Ciara Marie Kelly, William D. Tap, Nicola Fabbri et al. · 2019 · Clinical Cancer Research
66. Functional Profiling of Receptor Tyrosine Kinases and Downstream Signaling in Human Chondrosarcomas Identifies Pathways for Rational Targeted Therapy
    Yixiang Zhang, Jolieke G. van Oosterwijk, Ewa Sicińska, Samuel Moss, Stephen P. Remillard, Tom van Wezel, Claudia Bühnemann, Andrew Bassim Hassan, George D. Demetri, Judith V.M.G. Bovée et al. · 2013 · Clinical Cancer Research
67. MicroRNA-183 upregulates HIF-1α by targeting isocitrate dehydrogenase 2 (IDH2) in glioma cells
    Hirotomo Tanaka, Takashi Sasayama, Kazuhiro Tanaka, Satoshi Nakamizo, Masamitsu Nishihara, Katsu Mizukawa, Masaaki Kohta, Junji Koyama, Shigeru Miyake, Masaaki Taniguchi et al. · 2012 · Journal of Neuro-Oncology
68. Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations
    Stanley Zhou, Aislinn E. Treloar, Mathieu Lupien · 2016 · Cancer Discovery
69. Tumour-wide RNA splicing aberrations generate actionable public neoantigens
    Darwin W. Kwok, Nicholas O. Stevers, Iñaki Etxeberría, Takahide Nejo, Maggie Colton Cove, Lee H. Chen, Jangham Jung, Kaori Okada, Senthilnath Lakshmanachetty, Marco Gallus et al. · 2025 · Nature
70. Moving toward molecular classification of diffuse gliomas in adults
    Brett James Theeler, W. K. Alfred Yung, Gregory N. Fuller, John de Groot · 2012 · Neurology
71. Oncometabolites: A New Paradigm for Oncology, Metabolism, and the Clinical Laboratory
    Rebecca R. J. Collins, Khushbu Patel, William C. Putnam, Payal Kapur, Dinesh Rakheja · 2017 · Clinical Chemistry
72. Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer
    Sandeep Balu Shelar, Eun‐Hee Shim, Garrett J. Brinkley, Anirban Kundu, Francesca Carobbio, Tyler L. Poston, Jubilee C. Tan, Vishwas Parekh, Daniel G. Benson, David K. Crossman et al. · 2018 · Clinical Cancer Research
73. D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma
    Stefan Pusch, Leonille Schweizer, Ann-Christin Beck, Johanna-Marie Lehmler, Susanne Weißert, Jörg Balß, Aubry K. Miller, Andreas von Deimling · 2014 · Acta Neuropathologica Communications
74. Cancer-associated Isocitrate Dehydrogenase 1 (IDH1) R132H Mutation and d-2-Hydroxyglutarate Stimulate Glutamine Metabolism under Hypoxia
    Zachary J. Reitman, Christopher G. Duncan, Ethan C. Poteet, Ali Winters, Liang‐Jun Yan, David M. Gooden, Ivan Spasojević, László G. Boros, Shao-Hua Yang, Hai Yan · 2014 · Journal of Biological Chemistry
75. Osteosarcoma, chondrosarcoma and Ewing sarcoma: clinical aspects, biomarker discovery and liquid biopsy
    Aran, Veronica, Devalle, Sylvie, Meohas, Walter, Heringer, Manoela, Cunha Caruso, Anabela, Pinheiro Aguiar, Diego, Leite Duarte, Maria Eugênia, Moura Neto, Vivaldo · 2021 · Critical Reviews in Oncology/Hematology
76. Rare insights into cancer biology
    Julie Adam, Mingming Yang, Tomoyoshi Soga, Patrick J. Pollard · 2013 · Oncogene
77. A holistic view of cancer bioenergetics: mitochondrial function and respiration play fundamental roles in the development and progression of diverse tumors
    Md Maksudul Alam, Sneha Lal, Keely E. FitzGerald, Zhang Li · 2016 · Clinical and Translational Medicine
78. D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells
    Lingjun Zhang, Mia Dahl Sørensen, Bjarne Winther Kristensen, Guido Reifenberger, Thomas M. McIntyre, Feng Lin · 2018 · Clinical Cancer Research
79. Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma
    Motohiro Arai, Sumihito Nobusawa, Hayato Ikota, Sunao Takemura, Yoichi Nakazato · 2012 · Brain Tumor Pathology
80. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice
    Esra A. Akbay, Javid J. Moslehi, Camilla Laulund Christensen, Supriya K. Saha, Jeremy H. Tchaicha, Shakti H Ramkissoon, Kelly M. Stewart, Julián Carretero, Eiki Kikuchi, Haikuo Zhang et al. · 2014 · Genes & Development
81. Genetically-defined metabolic reprogramming in cancer
    Andrew R. Mullen, Ralph J. DeBerardinis · 2012 · Trends in Endocrinology and Metabolism
82. Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients
    Laura E. MacConaill, Elizabeth Garcia, Priyanka Shivdasani, Matthew D. Ducar, Ravali Adusumilli, Marc Breneiser, Mark N. Byrne, Lawrence P. Chung, Jodie Conneely, Lauren Crosby et al. · 2014 · Journal of Molecular Diagnostics
83. The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas
    Luyan Mu, Yu Long, Changlin Yang, Linchun Jin, Haipeng Tao, Haitao Ge, Yifan Emily Chang, Aida Karachi, Paul Scott Kubilis, Gabriel De Leon et al. · 2018 · Frontiers in Molecular Neuroscience
84. Mitochondrial dysfunction in cancer chemoresistance
    Nicoletta Guaragnella, Sergio Giannattasio, Loredana Moro · 2014 · Biochemical Pharmacology
85. Molecular analysis of diffuse intrinsic brainstem gliomas in adults
    Germán Reyes-Botero, Marine Giry, Karima Mokhtari, Marianne Labussière, Ahmed Idbaïh, Jean‐Yves Delattre, Florence Laigle–Donadey, Marc Sanson · 2013 · Journal of Neuro-Oncology
86. Molecular pathology and its diagnostic use in bone tumors
    Károly Szuhai, Anne‐Marie Cleton-Jansen, Pancras C.W. Hogendoorn, Judith V.M.G. Bovée · 2012 · Cancer Genetics
87. Enchondroma of the Hand: Evaluation and Management
    John D. Lubahn, Abdo Bachoura · 2016 · Journal of the American Academy of Orthopaedic Surgeons
88. Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
    Dusten J. Unruh, Makda Getachew Zewde, Adam Buss, Michael R. Drumm, Anh Nhat Tran, Denise M. Scholtens, Craig Horbinski · 2019 · Scientific Reports
89. Infratentorial IDH-mutant astrocytoma is a distinct subtype
    Rouzbeh Banan, Damian Stichel, Anja C. Bleck, Bujung Hong, Ulrich Lehmann, Abigail Kora Suwala, Annekathrin Reinhardt, Daniel Schrimpf, Rolf Buslei, Christine Stadelmann et al. · 2020 · Acta Neuropathologica
90. IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma
    Iwona A. Lugowska, Paweł Teterycz, Michał Mikuła, Maria Kulecka, Anna Kluska, Aneta Bałabas, Magdalena Piątkowska, Michał Wągrodzki, Andrzej Pieńkowski, Piotr Lukasz Rutkowski et al. · 2018 · Journal of Cancer
91. Chondrosarcoma-from Molecular Pathology to Novel Therapies
    Agnieszka E. Zając, Sylwia Kopeć, Bartłomiej Szostakowski, Mateusz Jacek Spalek, Michał Fiedorowicz, Elżbieta Bylina, Paulina Filipowicz, Anna Szumera‐Ciećkiewicz, Andrzej Tysarowski, Anna Malgorzata Czarnecka et al. · 2021 · Cancers
92. Interactions between epigenetics and metabolism in cancers
    Yun, Jihye, Johnson, Jared L., Hanigan, Christin L., Locasale, Jason W. · 2012 · Frontiers in Oncology
93. Update on Targets and Novel Treatment Options for High-Grade Osteosarcoma and Chondrosarcoma
    Jolieke G. van Oosterwijk, Jakob Anninga, Hans A. J. Gelderblom, Anne‐Marie Cleton-Jansen, Judith V.M.G. Bovée · 2013 · Hematology/Oncology Clinics of North America
94. Mutant IDH1 Enhances the Production of 2-Hydroxyglutarate Due to Its Kinetic Mechanism
    Alan R. Rendina, Beth Pietrak, Angela M. Smallwood, Huizhen Zhao, Hongwei Qi, Chad J. Quinn, Nicholas D. Adams, N.O. Concha, Chaya Duraiswami, Sara H. Thrall et al. · 2013 · Biochemistry
95. Hedgehog Pathway Inhibition in Chondrosarcoma Using the Smoothened Inhibitor IPI-926 Directly Inhibits Sarcoma Cell Growth
    Veronica T. Campbell, Puviindran Nadesan, Shabana Amanda Ali, Chang Ye Yale Wang, Heather Whetstone, Raymond W.M. Poon, Qingxia Wei, John Keilty, Jennifer Proctor, Lauren W. Wang et al. · 2014 · Molecular Cancer Therapeutics
96. The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
    Hao‐Yuan Wang, Kai Tang, Tingyu Liang, Weizhong Zhang, Ji-Ye Li, Wen Wang, Huimin Hu, Mingyang Li, Huiqing Wang, Xiao-Zheng He et al. · 2016 · Journal of Experimental & Clinical Cancer Research
97. PD-1 and PD-L1 expression in bone and soft tissue sarcomas
    Alireza Torabi, Clarissa N. Amaya, Frank H. Wians, Brad Allen Bryan · 2017 · Pathology
98. Emerging evidence for targeting mitochondrial metabolic dysfunction in cancer therapy
    Yueming Zhu, Angela Elizabeth Dean, Nobuo Horikoshi, Collin D. Heer, Douglas R. Spitz, David R. Gius · 2018 · Journal of Clinical Investigation
99. A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor
    Elhammali, Adnan, Ippolito, Joseph E., Collins, Lynne, Crowley, Jan, Marasa, Jayne, Piwnica-Worms, David · 2014 · Cancer Discovery
100. 2-HG Inhibits Necroptosis by Stimulating DNMT1-Dependent Hypermethylation of the RIP3 Promoter
     Yang, Zhentao, Jiang, Bin, Wang, Yan, Ni, Hengxiao, Zhang, Jia, Xia, Jinmei, Shi, Minggang, Hung, Li-Man, Ruan, Jingsong, Mak, Tak Wah et al. · 2017 · Cell Reports